BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma

被引：0

作者：

Yuhan Yan ^{[1
]}

Yixuan Tu ^{[1
]}

Qian Cheng ^{[1
]}

Jian Zhang ^{[1
]}

Erhua Wang ^{[1
]}

Zuqun Deng ^{[1
]}

Yan Yu ^{[1
]}

Liwen Wang ^{[1
]}

Rui Liu ^{[1
]}

Ling Chu ^{[2
]}

Liqing Kang ^{[3
]}

Jing Liu ^{[1
]}

Xin Li ^{[1
]}

机构：

[1] The Third Xiangya Hospital,Department of Hematology

[2] Central South University,Department of Pathology

[3] The Third Xiangya Hospital,undefined

[4] Central South University,undefined

[5] Shanghai Unicar-Therapy Bio-Medicine Technology Co,undefined

来源：

Journal of Translational Medicine | / 22卷 / 1期

关键词：

Relapsed/Refractory multiple myeloma (R/R MM); BCMA CAR T-cell therapy; Pomalidomide; Combination therapy;

D O I：

10.1186/s12967-024-05772-w

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] BCMA CAR-T Therapy Is Safe and Effective for Refractory/Relapsed Multiple Myeloma With Central Nervous System Involvement
Wang, Yiyun
Zu, Cheng
Teng, Xinyi
Yang, Li
Zhang, Mingming
Hong, Ruimin
Zhao, Houli
Cui, Jiazhen
Xu, Huijun
Hongsheng, Alex Chang
Hu, Yongxian
Huang, He
JOURNAL OF IMMUNOTHERAPY, 2022, 45 (01) : 25 - 34
[2] BCMA CAR-T-Cell Therapy in Combination with Long-Term Pomalidomide Is a Safe and Effective Treatment for Relapsed/Refractory Multiple Myeloma
Yan, Yuhan
Tu, Yixuan
Wu, De-Pei
Li, Xin
BLOOD, 2023, 142
[3] CAR-T Therapy in Relapsed Refractory Multiple Myeloma
Ding, Hong
Wu, Yu
CURRENT MEDICINAL CHEMISTRY, 2024, 31 (27) : 4362 - 4382
[4] Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma
Feng, Deming
Sun, Jian
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2020, 92 (02)
[5] Anti-BCMA CAR-T cell immunotherapy for relapsed or refractory multiple myeloma
Zhang, Xiaohui
Ouyang, Chenxi
Sun, Guofeng
Liu, Hongfeng
Qi, Junyuan
Suo, Xiaohui
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2023, 26 (04)
[6] Developing a Novel Anti-Bcma CAR-T for Relapsed or Refractory Multiple Myeloma
Yao, Xin
Zhu, Shigui
Huang, Jiaqi
Qu, Xiaoyan
Zhu, Judy
Wei, Yutian
Lan, Liping
Lv, Xiaoteng
Wu, Junfeng
Wang, Rirfei
Yang, Dingzhu
Zheng, Chengxiao
Zhao, DiJun
Fan, Lei
Huang, Fei
Lu, Hua
Zhang, Chaocan
Chen, Cheng
Li, Yanfeng
Ren, Jiaqiang
Zhang, Li
Humphries, Michael
Li, Jianyong
Yao, Yihong
BLOOD, 2019, 134
[7] A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma
Zhang, Hua
Gao, Lei
Liu, Li
Wang, Jishi
Wang, Sanbin
Gao, Li
Zhang, Cheng
Liu, Yao
Kong, Peiyan
Liu, Jia
He, Jiaping
Han, Yu
Shi, Hua
He, Yan
Ye, Xun
Zhao, Yi
Cao, Wei
Shen, Lianjun
Zhang, Xi
BLOOD, 2019, 134
[8] Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
Samer Al Hadidi
Aniko Szabo
Jean Esselmann
Lindsay Hammons
Munawwar Hussain
Yetunde Ogunsesan
Nishanth Thalambedu
Fatima Khan
Jaskirat Sethi
Abhishek Janardan
Sabarinath Venniyil Radhakrishnan
Sharmilan Thanendrarajan
Carolina Schinke
Binod Dhakal
Siegfried Janz
Saurabh Chhabra
Anita D’Souza
Maurizio Zangari
Frits van Rhee
Meera Mohan
Bone Marrow Transplantation, 2023, 58 : 443 - 445
[9] Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
Al Hadidi, Samer
Szabo, Aniko
Esselmann, Jean
Hammons, Lindsay
Hussain, Munawwar
Ogunsesan, Yetunde
Thalambedu, Nishanth
Khan, Fatima
Sethi, Jaskirat
Janardan, Abhishek
Radhakrishnan, Sabarinath Venniyil
Thanendrarajan, Sharmilan
Schinke, Carolina
Dhakal, Binod
Janz, Siegfried
Chhabra, Saurabh
D'Souza, Anita
Zangari, Maurizio
van Rhee, Frits
Mohan, Meera
BONE MARROW TRANSPLANTATION, 2023, 58 (04) : 443 - 445
[10] A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
Heng Mei
Chenggong Li
Huiwen Jiang
Xinying Zhao
Zhiping Huang
Dan Jin
Tao Guo
Haiming Kou
Lin Liu
Lu Tang
Ping Yin
Zhihui Wang
Lisha Ai
Sha Ke
Yimeng Xia
Jun Deng
Lei Chen
Li Cai
Chunyan Sun
Linghui Xia
Gaoquan Hua
Yu Hu
Journal of Hematology & Oncology, 14

← 1 2 3 4 5 →